Comparing 4 versus 8 Tepezza treatments for thyroid eye disease
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial compares two different lengths of treatment with Tepezza (teprotumumab) for thyroid eye disease. It aims to see if 4 treatments are as effective and safe as 8 treatments, which could mean fewer infusions for patients who respond early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have active thyroid eye disease (TED), which causes symptoms like eye bulging, swelling, or redness.
- You must be already receiving the standard Tepezza (teprotumumab) treatment for your TED.
- You must have shown clear improvement after the first 4 infusions of Tepezza.
- You must not have used Tepezza or other biologic medicines for TED before this trial.
- You must not have any hearing problems or medical conditions that make Tepezza unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
This trial tests a new version of an antibody treatment (teprotumumab) for people with active thyroid eye disease. It aims to reduce bulging and inflammation of the eyes, and you must have had symptoms for less than 9 months to join.
This study tests if the drug teprotumumab can help with symptoms of thyroid eye disease, such as bulging eyes, pain, or double vision. It is for adults who are beneficiaries of the Department of Defense (DOD).
This trial compares a newer medication (teprotumumab) with standard steroid treatment for people with thyroid eye disease and vision loss who are about to have urgent surgery to relieve pressure on the optic nerve. The goal is to see which approach better protects and restores vision after surgery.
This trial tests a new medicine (veligrotug) for people with thyroid eye disease whose symptoms returned after completing teprotumumab. It aims to see if veligrotug can help again.
This trial tests a new medication for people with long-term thyroid eye disease that has lasted over a year. The aim is to see if it can reduce symptoms like bulging and discomfort.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.